Thermo Fisher Scientific Inc. (NYSE:TMO) reported first-quarter 2025 adjusted earnings per share of $5.15 on Wednesday, beating the street view of $5.10.
Quarterly sales of $10.36 billion, almost flat year over year, outpaced the analyst consensus estimate of $10.23 billion. Organic revenue growth was 1%.
“We delivered very strong performance in the first quarter in a more uncertain macroeconomic environment, and I’m incredibly proud of our team’s execution,” said Marc Casper, chairman, president, and CEO of Thermo Fisher Scientific. “Our team leveraged the PPI Business System to drive operational excellence and enable our customers’ success.”
Casper added: “Thermo Fisher is incredibly well-positioned. Our experienced management team has a proven track record, and as the trusted partner to our customers, we will help them manage the current environment, identifying new opportunities and ultimately creating value for all our stakeholders.”
Also Read: 3M Spin-Off Solventum Targets Higher Margins, EPS Growth In 2025-2028 Strategy
Thermo Fisher’s adjusted operating income for the first quarter of 2025 was $2.27 billion, compared with $2.28 billion in the year-ago quarter.
Revenue from the Life Sciences Solutions Segment increased by 2.5% year over year to $2.34 billion. Analytical Instruments Segment sales were up 1.8% to $1.72 billion.
Specialty Diagnostics Segment revenues increased 3.5% to $1.15 billion, and Laboratory Products and Biopharma Services segment sales were down 1.5% at $5.64 billion.
Thermo Fisher Scientific agreed to acquire Solventum’s (NYSE:SOLV) Purification & Filtration business in February for approximately $4.1 billion in cash.
Solventum's Purification & Filtration business provides purification and filtration technologies for the production of biologics, medical technologies, and industrial applications.
Price Action: Thermo Fisher stock is trading 4.23% higher at $453.10 at the last check Wednesday.
Read Next:
Image: Shutterstock
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。